Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 14Lymphoma, Non-Hodgkin 10Breast Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell 5Lymphoma 5Solid Tumors 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Melanoma 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Arthritis, Rheumatoid 4Ovarian Neoplasms 3Lymphoma, Follicular 3Leukemia 3Hematologic Neoplasms 3Cytokine Release Syndrome 3Colorectal Neoplasms 3Burkitt Lymphoma 3Urinary Bladder Neoplasms 2Respiratory Distress Syndrome 2Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Fallopian Tube Neoplasms 2Craniopharyngioma 2Carcinoma, Hepatocellular 2

Interventions

Etoposide 7pegaspargase 5Methylprednisolone 4Dexamethasone 4Cyclophosphamide 3Alemtuzumab 3Gemcitabine 2Emapalumab 2Doxorubicin 2zanubrutinib 1tocilizumab 1sintilimab 1ruxolitinib 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Vincristine 1Thiotepa 1Tacrolimus 1Rituximab 1Prednisone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Methylprednisolone Hemisuccinate 1Methotrexate 1Melphalan 1EPOCH protocol 1Cytarabine 1Cisplatin 1Calcium Dobesilate 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphohistiocytosis, Hemophagocytic × tocilizumab × Clear all
NCT02385110 2024-01-17

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

M.D. Anderson Cancer Center

Phase 2 Completed
18 enrolled 10 charts
MyeloidOther hematologic neoplasm

Leukemia, Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡